Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Alverine is a direct relaxant of intestinal and uterine smooth muscle. It acts by inhibiting calcium channels and has no antimuscarinic or anticholinergic activity (Brenner 2021). It is used in the treatment of gastrointestinal disorders such as irritable bowel syndrome and in the treatment of dysmenorrhoea. Administered orally or in suppositories one to three times a day.
At the time of the last update, we found no published data on its excretion in breast milk.
Product with very few bibliographic references and marketed in only a few countries. The scarcity of known pharmacokinetic data does not allow for predicting possible excretion in breast milk.
Side effects are rare and mild, often no greater than those experienced with placebo. (Brenner 2021)
Until more published data on this drug in relation to breastfeeding is available, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.